Hemispherx Biopharma

Hemispherx Biopharma (NYSE MKT: HEB) is a biopharmaceutical company based in Philadelphia, Pennsylvania.[1] Founded in 1990, the company has 32 employees.[2]

The company has created an immunomodulatory double stranded RNA drug called Ampligen.[3] The company is developing Ampligen to use as a treatment for chronic fatigue syndrome.[4]

On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect a charge relating to an extension of the exercise period to certain warrants as of February 1999.

On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.[5]


References

  1. ↑ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 2009-08-24. Retrieved 24 August 2009.
  2. ↑ "Hemispherx Biopharma, Inc.". BusinessWeek. Archived from the original on 2009-08-24. Retrieved 24 August 2009.
  3. ↑ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 2009-08-24. Retrieved 24 August 2009.
  4. ↑ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.
  5. ↑ "Hemispherx delays 2005 statement".

External links

This article is issued from Wikipedia - version of the Friday, February 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.